logo
Plus   Neg
Share
Email

Halozyme: Genentech Reports Positive Outcome From Phase III Study Using ENHANZE

Halozyme Therapeutics, Inc. (HALO) said the phase III FeDeriCa trial, a global study conducted by Genentech using combination of pertuzumab and trastuzumab using Halozyme's ENHANZE drug delivery technology, met its primary endpoint. Halozyme said the results of the study is an important development for the ENHANZE technology.

Helen Torley, CEO, said: "This is the first study to combine two therapeutic antibodies as a single fixed-dose subcutaneous formulation utilizing our ENHANZE technology, thereby providing patients with HER2-positive breast cancer the possibility of a faster treatment option."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
NBCUniversal unveiled Peacock, a free premium ad-supported streaming service with subscription tiers offering more than 600 movies and 400 series. Peacock will be available on April 15 for Comcast's Xfinity X1 and Flex customers and on July 15 for the rest of the country. NBC is offering Peacock... The number of Amazon Prime members in the U.S. is growing slowly, but steadily, a recent study has shown. According to the survey by the Consumer Intelligence Research Partners, LLC or CIRP, the number of Amazon Prime members in the U.S. is estimated to have risen to 112 million in December 2019 from just over 100 million in the same period of the prior year. Medical device manufacturer Cardinal Health will soon recall certain Level 3 surgical gowns or PreSource procedural packs that contain these gowns following warning that they may not be sterile, the U.S. Food and Drug Administration said in a statement. The health regulator said it is working with the company to find out the specific product lots that are impacted.
RELATED NEWS
Follow RTT
>